Equillium Inc. (EQ)
0.47
0.00 (0.21%)
At close: Apr 04, 2025, 3:59 PM
0.50
6.27%
After-hours: Apr 04, 2025, 04:13 PM EDT
0.21% (1D)
| Bid | 0.36 |
| Market Cap | 16.63M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -0.23 |
| PE Ratio (ttm) | -2.03 |
| Forward PE | -0.63 |
| Analyst | Hold |
| Ask | 0.57 |
| Volume | 157,799 |
| Avg. Volume (20D) | 820,070 |
| Open | 0.46 |
| Previous Close | 0.47 |
| Day's Range | 0.44 - 0.53 |
| 52-Week Range | 0.36 - 2.26 |
| Beta | 1.86 |
About EQ
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 12, 2018
Employees 35
Stock Exchange NASDAQ
Ticker Symbol EQ
Website https://equilliumbio.com
Analyst Forecast
According to 3 analyst ratings, the average rating for EQ stock is "Hold." The 12-month stock price forecast is $3, which is an increase of 542.40% from the latest price.
Stock Forecasts1 week ago
-16.93%
Equillium shares are trading lower after Leerink P...
Unlock content with
Pro Subscription
1 week ago
-35.62%
Equillium shares are trading lower after the company announced the results of the Phase 3 EQUATOR study of Itolizumab, which showed that it did not improve complete or overall response rates.
